Suppr超能文献

接受噬菌体治疗患者血清对噬菌体的中和作用。

Phage neutralization by sera of patients receiving phage therapy.

作者信息

Łusiak-Szelachowska Marzanna, Zaczek Maciej, Weber-Dąbrowska Beata, Międzybrodzki Ryszard, Kłak Marlena, Fortuna Wojciech, Letkiewicz Sławomir, Rogóż Paweł, Szufnarowski Krzysztof, Jończyk-Matysiak Ewa, Owczarek Barbara, Górski Andrzej

出版信息

Viral Immunol. 2014 Aug;27(6):295-304. doi: 10.1089/vim.2013.0128. Epub 2014 Jun 3.

Abstract

The aim of our investigation was to verify whether phage therapy (PT) can induce antiphage antibodies. The antiphage activity was determined in sera from 122 patients from the Phage Therapy Unit in Wrocław with bacterial infections before and during PT, and in sera from 30 healthy volunteers using a neutralization test. Furthermore, levels of antiphage antibodies were investigated in sera of 19 patients receiving staphylococcal phages and sera of 20 healthy volunteers using enzyme-linked immunosorbent assay. The phages were administered orally, locally, orally/locally, intrarectally, or orally/intrarectally. The rate of phage inactivation (K) estimated the level of phages' neutralization by human sera. Low K rates were found in sera of healthy volunteers (K ≤ 1.73). Low K rates were detected before PT (K ≤ 1.64). High antiphage activity of sera K > 18 was observed in 12.3% of examined patients (n = 15) treated with phages locally (n = 13) or locally/orally (n = 2) from 15 to 60 days of PT. High K rates were found in patients treated with some Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecalis phages. Low K rates were observed during PT in sera of patients using phages orally (K ≤ 1.04). Increased inactivation of phages by sera of patients receiving PT decreased after therapy. These results suggest that the antiphage activity in patients' sera depends on the route of phage administration and phage type. The induction of antiphage activity of sera during or after PT does not exclude a favorable result of PT.

摘要

我们研究的目的是验证噬菌体疗法(PT)是否能诱导抗噬菌体抗体。采用中和试验测定了弗罗茨瓦夫噬菌体治疗科122例细菌感染患者在接受PT前和治疗期间血清中的抗噬菌体活性,以及30名健康志愿者血清中的抗噬菌体活性。此外,采用酶联免疫吸附测定法研究了19例接受葡萄球菌噬菌体治疗的患者血清和20名健康志愿者血清中的抗噬菌体抗体水平。噬菌体通过口服、局部、口服/局部、直肠内或口服/直肠内给药。噬菌体失活率(K)估计了人血清对噬菌体的中和水平。在健康志愿者血清中发现低K率(K≤1.73)。在PT前检测到低K率(K≤1.64)。在接受噬菌体局部治疗(n = 13)或局部/口服治疗(n = 2)的15至60天的12.3%的受检患者(n = 15)中观察到血清的高抗噬菌体活性(K>18)。在使用某些金黄色葡萄球菌、铜绿假单胞菌和粪肠球菌噬菌体治疗的患者中发现高K率。在口服噬菌体的患者血清中,PT期间观察到低K率(K≤1.04)。接受PT的患者血清对噬菌体的失活作用在治疗后降低。这些结果表明,患者血清中的抗噬菌体活性取决于噬菌体给药途径和噬菌体类型。PT期间或之后血清抗噬菌体活性的诱导并不排除PT取得良好效果的可能性。

相似文献

1
Phage neutralization by sera of patients receiving phage therapy.
Viral Immunol. 2014 Aug;27(6):295-304. doi: 10.1089/vim.2013.0128. Epub 2014 Jun 3.
2
Antiphage activity of sera during phage therapy in relation to its outcome.
Future Microbiol. 2017 Feb;12:109-117. doi: 10.2217/fmb-2016-0156. Epub 2016 Sep 19.
3
Antibody Production in Response to Staphylococcal MS-1 Phage Cocktail in Patients Undergoing Phage Therapy.
Front Microbiol. 2016 Oct 24;7:1681. doi: 10.3389/fmicb.2016.01681. eCollection 2016.
5
Antigenicity of converting phages obtained from Clostridium botulinum types C and D.
Infect Immun. 1976 Mar;13(3):855-60. doi: 10.1128/iai.13.3.855-860.1976.
6
Comparative studies with tox plus and tox minus corynebacteriophages.
J Virol. 1970 Jun;5(6):783-4. doi: 10.1128/JVI.5.6.783-794.1970.
7
Anti-phage serum antibody responses and the outcome of phage therapy.
Folia Microbiol (Praha). 2021 Feb;66(1):127-131. doi: 10.1007/s12223-020-00835-z. Epub 2020 Oct 30.
8
Correlation of Phage Resistance with the Numbers and Types of Antiphage Systems.
Int J Mol Sci. 2024 Jan 24;25(3):1424. doi: 10.3390/ijms25031424.
9
Phage as a modulator of immune responses: practical implications for phage therapy.
Adv Virus Res. 2012;83:41-71. doi: 10.1016/B978-0-12-394438-2.00002-5.
10
Evaluation of the impact of repeated intravenous phage doses on mammalian host-phage interactions.
J Virol. 2024 Jan 23;98(1):e0135923. doi: 10.1128/jvi.01359-23. Epub 2023 Dec 12.

引用本文的文献

2
Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead.
Int Urogynecol J. 2025 May 13. doi: 10.1007/s00192-025-06136-8.
3
Phage therapy in the management of respiratory and pulmonary infections: a systematic review.
Ther Adv Infect Dis. 2025 Jan 24;12:20499361241307841. doi: 10.1177/20499361241307841. eCollection 2025 Jan-Dec.
4
5
Phage therapy could be key to conquering persistent bacterial lung infections in children.
NPJ Antimicrob Resist. 2024 Oct 10;2(1):31. doi: 10.1038/s44259-024-00045-4.
6
Bacteriophage as a novel therapeutic approach for killing multidrug-resistant ST131 clone.
Front Microbiol. 2024 Dec 12;15:1455710. doi: 10.3389/fmicb.2024.1455710. eCollection 2024.
7
Phage therapy to treat cystic fibrosis complex lung infections: perspectives and challenges.
Front Microbiol. 2024 Oct 18;15:1476041. doi: 10.3389/fmicb.2024.1476041. eCollection 2024.
8
Periodontitis: etiology, conventional treatments, and emerging bacteriophage and predatory bacteria therapies.
Front Microbiol. 2024 Sep 26;15:1469414. doi: 10.3389/fmicb.2024.1469414. eCollection 2024.
9
Phage-specific antibodies: are they a hurdle for the success of phage therapy?
Essays Biochem. 2024 Dec 17;68(5):633-644. doi: 10.1042/EBC20240024.
10
Mini review advantages and limitations of lytic phages compared with chemical antibiotics to combat bacterial infections.
Heliyon. 2024 Jul 18;10(14):e34849. doi: 10.1016/j.heliyon.2024.e34849. eCollection 2024 Jul 30.

本文引用的文献

1
Clinical aspects of phage therapy.
Adv Virus Res. 2012;83:73-121. doi: 10.1016/B978-0-12-394438-2.00003-7.
2
Phage as a modulator of immune responses: practical implications for phage therapy.
Adv Virus Res. 2012;83:41-71. doi: 10.1016/B978-0-12-394438-2.00002-5.
3
Effect of rituximab on human in vivo antibody immune responses.
J Allergy Clin Immunol. 2011 Dec;128(6):1295-1302.e5. doi: 10.1016/j.jaci.2011.08.008. Epub 2011 Sep 9.
4
Preparation and characterization of anti-phage serum.
Methods Mol Biol. 2009;501:287-92. doi: 10.1007/978-1-60327-164-6_24.
5
Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy.
Antimicrob Agents Chemother. 2005 Jul;49(7):2874-8. doi: 10.1128/AAC.49.7.2874-2878.2005.
9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验